Abstract:e13104 Background: Apoptosis proteins are frequently upregulated in human cancers and are associated with resistance to therapeutic agents and poor outcomes. TQB3728 antagonizes the function of inhibitor of apoptosis proteins (IAPs), thereby inhibiting NF-кB signaling pathways and promoting cancer cell death. This first-in-human study aims to evaluate the maximum-tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, and antitumor activity of TQB3728 in patients with advanced solid tumors after the failure of standard therapy. Methods: This study combined an accelerated dose titration design with a 3+3 dose escalation design. Three dosage schedules were explored. First of all, TQB3728 was given orally once a week, on a 28-day cycle (DS1). The starting dose of 25mg was escalated by 100% in a single patient until the third dose, then diverted to a 3+3 dose escalation design. The other two dosage schedules were TQB3728 given once daily on days 1-14 every 3 weeks (DS2) and daily every 4 weeks (DS3). The primary endpoint was safety, maximum tolerated or maximum administered dose (MTD), and the secondary endpoints were pharmacokinetics, pharmacodynamics, and tumor response per RECIST v1.1. Results: As of Dec 15, 2023, 23 patients (pts) received at least one dose of TQB3728 (dose range, 25 to 600mg). Based on the pharmacokinetics and safety of DS1, then DS2 (dose range, 100 to 200mg) and DS3 (dose range, 100 to 200mg) were investigated. The median follow-up period was 8.5m (range, 0.5 to 25m). No dose-limited toxicity and cytokine release syndrome were observed. The main treatment-related adverse events (TRAEs) were nausea (56.5%), lymphopenia (56.5%), dizziness (39.1%), hypersomnia (34.8%), increased aspartate aminotransferase (30.4%), increased alanine aminotransferase (26.1%), vomiting (26.1%), anemia (21.7%), decreased appetite (21.7%), and grade≥3 TRAE were lymphopenia (8.7%), anemia (4.4%). As for DS1, the average Tmax and t1/2 were 2 h and 9.6 h, respectively. The exposure did not increase with the dose above 150mg. Moreover, the average Tmax was about 2.3 h and 0.8 h, and t1/2 was 6.6 h and 7 h in DS2 and DS3, respectively. There was no significant accumulation with continuous medication. Additionally, Plasma MCP-1 increased at 3-6h postdose at high dose; cIAP-1 levels in PBMCs were undetected. Two pts (8.7%) had stable disease >6 weeks as the best treatment response. Conclusions: TQB3728 was well tolerated at doses up to 600mg but had limited anti-tumor activity in advanced solid tumor. According to the preliminary results, TQB3728 administered orally in combination with conventional chemo-radiotherapy is under exploration. Clinical trial information: NCT04523285 .

Single-Dose and Multiple-Dose Pharmacokinetic Study of Tegafur, Gimeracil, and Oteracil Potassium Tablets in Patients with Advanced Solid Tumors

Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study

Phase I, Dose-Escalation Study of the Investigational Drug D07001-F4, an Oral Formulation of Gemcitabine HCl, in Patients (pts) with Advanced Solid Tumors or Lymphoma

MA16.06 Phase I/II Study of AC0010, Mutant-Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation

Observation on Efficacy of Tegafur Gimeracil Oteracil Potassium Capsules Combined with Oxaliplatin in Treatment of Advanced Gastric CancerΔ

Clinical Evaluation of Tegafur-Gimeracil-oteracil Potassium Combined with Oxaliplatin for Recurrent and Metastatic Gastric Cancer

Comparison of Pharmacokinetics, Efficacy and Toxicity Profile of Gemcitabine Using Two Different Administration Regimens in Chinese Patients with Non-Small-cell Lung Cancer

Clinical Observation on Compound Tegafur for Advanced Gastric Cancer

Clinical Study on Gimeracil and Oteracil Porassium Tablet Combined with Cisplatin in Chemotherapy of Advanced Gastric Cancer

Fluorouracil Supplemented with Oxaliplatin or Irinotecan for Solid Tumors: Indications from Clinical Characteristics and Health Outcomes of Patients

CLINICAL STUDY OF TEGAFUR COMBINED WITH OXALIPLATIN FOR ADVANCED COLORECTAL CANCER

First-in-Human Phase 1 Study of ES-072, an Oral Mutant-Selective EGFR T790M Inhibitor, in Non–Small-Cell Lung Cancer

Clinical Study of Compound Tegafur and Oteracil Potassium Sustained Capsules (S-1) in the Treatment of Advanced Gastric Cancer

A Phase I, Open-Label, Nonrandomized, Pharmacokinetic Study of Trifluridine/tipiracil (TAS-102) in Chinese Patients with Solid Tumors.

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.

473P Phase I Study of GFH018, a Small Molecular TGF-βRI Inhibitor, in Patients (pts) with Advanced Solid Tumors

Tegafur Combined with Oxaliplatin and 5-FU Versus FOLFOX4 for Advanced Colorectal Cancer: a Randomized Controlled Study

Clinical Observation on Gimeracil and Oteracil Porassium Capsules Combined with Irinotecan for Advanced Colorectal Cancer

A bioequivalence study of trifluridine/tipiracil tablets in Chinese metastatic colorectal cancer patients under fed conditions

Phase I Study of TQB3728 Tablets, an Oral Inhibitor of Apoptosis Proteins in Patients with Advanced Solid Tumor.

Cpaa_a_232104 21..33